Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
55.20
-0.43 (-0.77%)
Jun 10, 2026, 12:15 PM EDT - Market open
Royalty Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 586.4 | 618.7 | 929.03 | 477.01 | 1,711 | 1,541 |
Short-Term Investments | - | - | - | - | 24.42 | 581.87 |
Cash & Short-Term Investments | 586.4 | 618.7 | 929.03 | 477.01 | 1,735 | 2,123 |
Cash Growth | -46.09% | -33.40% | 94.76% | -72.51% | -18.27% | 6.57% |
Accounts Receivable | 27.51 | 29.32 | 26.96 | 22.41 | 36.6 | 68.31 |
Other Current Assets | 811.91 | 880.08 | 846.16 | 774.78 | 783.14 | 686.98 |
Total Current Assets | 1,426 | 1,528 | 1,802 | 1,274 | 2,555 | 2,878 |
Other Intangible Assets | - | - | - | - | - | 5.67 |
Goodwill | 924.63 | 924.63 | - | - | - | - |
Long-Term Investments | 845.77 | 880.28 | 1,260 | 1,012 | 735.82 | 909.59 |
Other Long-Term Assets | 16,619 | 16,288 | 15,161 | 14,095 | 13,523 | 13,722 |
Total Assets | 19,815 | 19,621 | 18,223 | 16,382 | 16,814 | 17,516 |
Accounts Payable | 25.48 | 19.4 | 13.37 | 15.17 | 7.91 | 5.62 |
Current Portion of Long-Term Debt | 380 | 380 | 997.77 | - | 997.51 | - |
Other Current Liabilities | 130.2 | 236.81 | 242.47 | 146.21 | 161.37 | 165.63 |
Total Current Liabilities | 535.68 | 636.21 | 1,254 | 161.38 | 1,167 | 171.25 |
Long-Term Debt | 8,576 | 8,571 | 6,615 | 6,135 | 6,119 | 7,096 |
Other Long-Term Liabilities | 766.46 | 698.71 | 12.08 | 0.9 | 2.5 | - |
Total Long-Term Liabilities | 9,343 | 9,270 | 6,627 | 6,136 | 6,121 | 7,096 |
Total Liabilities | 9,879 | 9,906 | 7,880 | 6,298 | 7,288 | 7,267 |
Common Stock | 0.05 | 0.04 | 0.05 | 0.05 | 0.04 | 0.04 |
Treasury Stock | -2.71 | -2.61 | -2.66 | -2.63 | -2.81 | 16.49 |
Additional Paid-in Capital | 4,384 | 4,123 | 4,103 | 4,011 | 3,666 | 3,508 |
Accumulated Other Comprehensive Income | - | - | - | - | - | -2.72 |
Retained Earnings | 2,507 | 2,356 | 2,846 | 2,518 | 1,965 | 2,255 |
Total Common Shareholders' Equity | 6,888 | 6,477 | 6,947 | 6,526 | 5,628 | 5,777 |
Minority Interest | 3,048 | 3,238 | 3,396 | 3,558 | 3,897 | 4,472 |
Shareholders' Equity | 9,937 | 9,715 | 10,342 | 10,084 | 9,525 | 10,249 |
Total Liabilities & Equity | 19,815 | 19,621 | 18,223 | 16,382 | 16,814 | 17,516 |
Total Debt | 8,956 | 8,951 | 7,612 | 6,135 | 7,116 | 7,096 |
Net Cash (Debt) | -8,370 | -8,332 | -6,683 | -5,658 | -5,381 | -4,973 |
Net Cash Per Share | -19.32 | -14.76 | -11.25 | -9.38 | -12.29 | -11.99 |
Book Value | 6,888 | 6,477 | 6,947 | 6,526 | 5,628 | 5,777 |
Book Value Per Share | 15.90 | 11.47 | 11.69 | 10.83 | 12.85 | 13.93 |
Tangible Book Value | 5,964 | 5,552 | 6,947 | 6,526 | 5,628 | 5,771 |
Tangible Book Value Per Share | 13.77 | 9.84 | 11.69 | 10.83 | 12.85 | 13.91 |